Speciality pharmaceutical group Essential Pharma has concluded the acquisition of Reminyl oral capsules from Johnson & Johnson company Janssen Pharmaceutica.

The strategic move enhances Essential Pharma’s portfolio of central nervous system (CNS) medicines and expands its global footprint, particularly in Asia-Pacific.

A cholinesterase inhibitor, Reminyl is an established CNS drug for mild to moderately severe dementia of the Alzheimer type.

Essential Pharma will now hold rights to Reminyl in the European Economic Area, South Korea, Thailand and all other existing markets for this product.

The deal excludes the UK and Ireland, Japan and Latin America.

The acquisition aligns with Essential Pharma’s focus on CNS, gastroenterology, ophthalmology and rare diseases.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Essential operates in more than 70 countries and is supported by healthcare investment firm Gyrus Capital.

Essential CEO Emma Johnson stated: “Our acquisition of rights to Reminyl in these markets will ensure Alzheimer’s patients and caregivers in those regions have continued access to this vital medicine.

“The acquisition represents a significant and synergistic addition to our concentrated portfolio of CNS products, further expanding our global presence and solidifying our position as a leading speciality pharma group.”

The latest development comes after Essential Pharma acquired clinical-stage pharmaceutical company Renaissance Pharma for an undisclosed sum in April 2024.

Renaissance develops treatments for paediatric rare diseases, with its lead asset, Hu14.18K322A, currently being analysed in a Phase II clinical trial to treat high-risk neuroblastoma.